Order of the National Green Tribunal in the matter of News Item titled "2 killed in blast at illegal cracker unit in Thanjavur appearing in The Hindu dated 19.05.2025". The application is registered suo-motu on the basis of the news item titled 2 killed in blast at illegal cracker unit …
THE hurdles that pharmaceutical companies face in accessing global markets may now ease. The drug regulator's office is likely to extend the tenure of export licence and other approvals from one year to at least three years. The move is expected to help many pharma companies that export huge quantities …
Drug-maker filed response in US court yesterday. Under fire in the United States for giving distorted information on the generic drugs it sold, Ranbaxy Laboratories today said that it will file all relevant information within a month after which the legal case initiated against it by the US government will …
Drug Regulatory System In India Has Abysmal Standards And There's No Credible Mechanism To Monitor Adverse Drug Reactions K G Narendranath NEW DELHI IT'S PRESUMPTUOUS to comment on the verity of the US department of justice allegation that Ranbaxy has mixed up bulk drugs procured from approved and unapproved sources, …
New US rules to free clinical trials of ethics it is alleged that Johnson and Johnson carried out clinical trials of its anti-psychotic drug, Risperdal, in Gujarat three years ago without the informed consent of patients. The study also used placebos despite drugs being available for treatment. Both these actions …
The state government has ayed proposals for setting up three pharmaceutical units with an investment of Rs 275 crore in special economic zones at Indore and Gwalior. The Glenmark group would establish two units - Rs 175 cr - while Teva API India group would set up one over 29 …
Govt Looking At Several Ways To Ensure Availability Of Essential Drugs THERE may be good news for the pharma industry, which has been facing price caps and fighting high input costs. The government is learnt to be considering liberalising the 10% mandatory cap on price hike for drugs outside the …
Khomba Singh NEW DELHI THERE may be good news for the pharma industry, which has been facing price caps and fighting high input costs. The government is learnt to be considering liberalising the 10% mandatory cap on price hike for drugs outside price control. Non-scheduled drugs or drugs outside the …
An Indian company buying a foreign company or a foreign company acquiring an Indian company should not inflate or deflate our pride -Jaskaran Singh Dhami We got puffed up with pride when Lakshmi Mittal made ripples in the business world by buying Arcelor. The tugging of 'Corus' by Tatas added …
GlaxoSmithKline, the UK-based pharmaceutical company, is unlikely to receive US approval for its key cervical cancer vaccine until 2010 at the earliest, under a new timetable it released on Monday. After requests for fresh information on Cervarix from the Food & Drug Administration in December, GSK said it had decided …
Melody Petersen covered the pharmaceutical beat for The New York Times for four years. In 1997, her investigative reporting won a Gerald Loeb Award, one of the highest honors in business journalism. She is the author of Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines …
Anaerobic treatment has gained tremendous success over the past two decades for treatment of industrial effluents. Over the past 30 years, the popularity of anaerobic wastewater treatment has increased as public utilities and industries have utilized its considerable benefits. Low biomass production, low nutrient requirements and the energy production in …
GURCHARAN DAS For some years now i have been on the board of Ranbaxy and have watched with admiration as the company transformed itself into India's first real multinational. I have seen it inspire a dozen other companies and helped create a world-class generic drugs industry that is feared by …
NEW DELHI: The Cabinet Committee on Economic Affairs on Thursday approved extending grants-in-aid to the pharmaceutical industry for research and development projects, involving clinical trials to develop new drugs for neglected diseases of tropical regions, under the Drugs and Pharmaceuticals Research Programme (DPRP) of the Department of Science and Technology. …
SUN Pharmaceutical Industries, the country's most valuable drugmaker, has decided to launch a hostile bid for Israel's Taro Pharmaceutical Industries. This is a rare instance of an Indian company making an unsolicited bid for a foreign firm. The move follows Taro's rejection of a merger agreement with Sun last month. …
Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration to manufacture and market the generic version of Roche's Valcyte (valganciclovir hydrochloride Tablets, 450 mg), a drug used for treatment of cytomegalovirus retinitis in patients afflicted with AIDS. Being the first company to apply for the marketing …
Has Malvinder Singh truly freed Ranbaxy from risk by opting for an out-of-court settlement with Pfizer over Lipitor as he has claimed? The markets and analysts certainly thought otherwise. Investors dumped the Ranbaxy stock last week after the company announced that it had closed the feud with Pfizer over cholesterol …
Israel-based Taro Pharmaceuticals has sued its proposed buyer Sun Pharmaceutical Industries in an Israel court, for allegedly thwarting attempts to sell off Taro's subsidiary with drug-making facilities in Ireland to a group of investors. In a letter to Taro shareholders, the firm's Chairman Barrie Levitt said on June 15 that …
In a decision that will go a long way in soothing people living with HIV/AIDS (PLHAs), the Indian patent office today turned down the claim of a drug company to patent nevirapine. The drug is critical to HIV/AIDS treatment strategy, and is a crucial part of treatment for children affected …
Subject to the approval of the shareholders and the usual regulatory and statutory rubber stamps, India's largest pharmaceutical company, Ranbaxy Laboratories, is expected, by the end of March 2009 to become a subsidiary of Daiichi Sankyo, one of the leading pharmaceutical companies of Japan. Ranbaxy came into existence in 1937 …
